DEVELOPMENT OF POST COVID DIABETES MELLITUS: CAUSES AND EFFECTS
DOI:
https://doi.org/10.47820/recima21.v2i10.804Keywords:
Covid-19, Hyperglicemia, Diabetes Mellitus, ACE2, SARS-Cov-2 mechanismAbstract
Introduction: The association between COVID-19 and Diabetes Mellitus 2 (DM2) is evidenced by the affinity between the SARS-CoV-2 virus for binding sites of the Angiotensin-Converting Enzyme 2 (ACE2). ACE2 is a molecule abundantly expressed in cells of the endothelium, lungs and other organs, including the pancreatic islets. Objective: Perform an analysis in the current literature on cases of infection by COVID-19 responsible for triggering DM2. Materials and methods: This is a systematic literature review. Articles were selected from the Pubmed, Academic Google and Scielo databases, from March 2020 to March 2020. For the research, the following terms were used: "Covid 19", "Hyperglycemia", "Diabetes Mellitus", "ACE2", "Sars-Cov-2 mechanisms", with Health Sciences Descriptors (DeCS) standardized and combined by Boolean operators. After the inclusion and exclusion criteria, 16 articles were selected for review. Results: The affinity for ACE2 receptors allows SARS-CoV-2 to act on the pancreas, which can lead to peripheral insulin resistance and, therefore, to hyperglycemia. In most cases, the condition does not resolve at the end of the disease, leading to DM2. Conclusion: Since ACE2 is a receptor for the entry of SARS-Cov-2 in several tissues, including the pancreatic islets, people with greater expression of it on the cell surface are more likely to be infected by COVID-19. Furthermore, it is likely that the amount of glycosylated ACE2 receptors exerts an influence on this process. Therefore, one of the complications of COVID-19 may be the development of DM2.
Downloads
References
BRUFSKY, Adam. Hyperglycemia, hydroxychloroquine, and the COVID‐19 pandemic. Journal of medical virology, v. 92, n. 7, p. 770-775, 2020. Disponível em: https://doi.org/10.1002/jmv.25887
CERIELLO A, et al. Why is hyperglycaemia worsening COVID‐19 and its prognosis? Diabetes Obes Metab, 22: 1951-1952. 2020.
CERIELLO, A. Hyperglycemia and COVID-19: What was known and what is really new? Diabetes research and clinical practice, 167, 108383. 2020. Disponível em: https://doi.org/10.1016/j.diabres.2020.108383
ESKANDARANI RM, et al. Diabetic Ketoacidosis on Hospitalization with COVID-19 in a Previously Nondiabetic Patient: A Review of Pathophysiology. Clinical Medicine Insights: Endocrinology and Diabetes. January 2020. Disponivel em: https://doi.org/10.1177/1179551420984125
GHEBLAWI M, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020 May 8;126(10):1456-1474. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32264791/
GUO W, et al. Diabetes is a risk factor for the progression and prognosis of COVID‐19. Diabetes/metabolism research and reviews, v. 36, n. 7, p. e3319, 2020.
GUPTA A, et al. Extrapulmonary manifestations of COVID-19. Nat Med 26, 1017–1032. 2020. Disponível em: https://www.nature.com/articles/s41591-020-0968-3
ILIAS I, et al. Glycemia, Beta-Cell Function and Sensitivity to Insulin in Mildly to Critically Ill Covid-19 Patients. Medicina (Kaunas). 2021 Jan 14;57(1):68.
LIM S, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 17, 11–30 (2021). Disponível em: https://www.nature.com/articles/s41574-020-00435-4
PAL R, et al. “COVID-19, diabetes mellitus and ACE2: The conundrum”, 29 Março de 2020. Disponível em: https://doi.org/10.1016/j.diabres.2020.108132
PERROTA F, et al. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? Respiratory Medicine. [s.l.], v.168:105996, Jul. 2020.
RUBINO, Francesco et al. New-Onset Diabetes in Covid-19. The New England Journal of Medicine. [s.l.], v.8, n.383, p.789-790, Jun/Ago. 2020.
SEOW CJ, et al. Non autoimmune type 1B diabetes after mild COVID‐19: Report of three cases. Diabetes Metab Res Rev. 2021. Disponível em: https://doi.org/10.1002/dmrr.3438
Singh, AK, et al. “Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19.” Diabetes research and clinical practice vol. 167 (2020). Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445123/
Wu C, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med [Internet]; 2020
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2021 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
